Early Anti-TNFα Therapy Cuts Perianal Fistula Complications in Pediatric Crohn Disease

Follow Drugslib on

Medically reviewed by Drugs.com.

By Elana Gotkine HealthDay Reporter

FRIDAY, Jan. 3, 2025 -- For pediatric patients with Crohn disease, early anti-tumor necrosis factor-alpha (anti-TNFα) therapy is beneficial in preventing the development of perianal fistula complications (PFCs), according to a study published online Dec. 12 in Gut.

Jeremy Adler, M.D., from the University of Michigan in Ann Arbor, and colleagues examined whether early anti-TNFα therapy prevents PFCs in pediatric patients with Crohn disease. Participants had never experienced PFCs 30 days after study enrollment. Nearest-neighbor propensity score-matched triad analyses were conducted. A total of 447 matched patients without perianal fistula were included in the study.

The researchers observed a significant association for the presence of nonpenetrating perianal lesions (large skin tags, ulcers, and/or fissures) with PFC development (odds ratio, 4.08). The odds of PFCs were significantly reduced in association with early anti-TNFα therapy (odds ratio, 0.18). Among patients with perianal lesions, the odds of PFC development were further reduced in association with anti-TNFα therapy (odds ratio, 0.055). A reduced risk for PFCs was not seen in association with any other treatment group.

"Based on these findings, which corroborate prior studies, early anti-TNFα therapy should be recommended for pediatric patients at increased risk in order to prevent PFCs, serious complications, which are difficult to treat," the authors write. "The specific timing of how early anti-TNFα therapy should be introduced for different patient populations requires further study."

One author disclosed receipt of consulting fees from Janssen Research & Development.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2025-01-05 00:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords